VJHemOnc is committed to improving our service to you

EHA 2020 | ENDURANCE: RVD vs KrD for myeloma

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses ENDURANCE (NCT01863550), which investigated the use of bortezomib, lenalidomide, and dexamethasone (RVD) compared to carfilzomib, lenalidomide, and dexamethasone (KrD) in newly-diagnosed multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter